Neuraxis (NRXS) risk factors
Item 1A of every Neuraxis, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors50 risks2 reworded
Neuraxis shifted from a sole manufacturer to relying on two contract manufacturers for product production. The AMA accepted a Category I CPT Code for PENFS replacing the old CAT III code, with utilization effective January 1, 2026.
Filed Mar 19, 2026 - FY2024 10-K risk factors50 risks
Neuraxis faces significant operating losses since 2011 while trying to commercialize neuromodulation therapies for children like the IB-Stim device. The business heavily relies on third-party manufacturers, single-source component suppliers, and adequate insurance reimbursement codes. Extensive FDA and international regulations govern clinical trials, quality systems, marketing, and ongoing product compliance.
Filed Mar 20, 2025